EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Towards Precision Medicine in Metastatic Renal Cell Carcinoma: The Role of Emerging Biomarkers

Rugile Pikturniene, Alvydas Cesas, Sonata Jarmalaite, Edita Baltruskeviciene iD, Vincas Urbonas iD

Cancers · 13.04.2026 · 18 (8) · 1228

DOI: 10.3390/cancers18081228 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.04.2026. Verfasst von Rugile Pikturniene und 4 weiteren Autor:innen. Beteiligte Einrichtung: Life Sciences Center, Institute of Biosciences, Vilnius University, 01513 Vilnius, Lithuania. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RCC remains a therapeutically challenging malignancy, particularly in its metastatic stage, in which treatment resistance and limited response durability persist despite recent advances in immunotherapy and targeted therapies. Although immune checkpoint inhibitors (ICIs) have significantly improved outcomes for a subset of patients, reliable prognostic and predictive biomarkers to guide therapy selection are still lacking. Current clinical models, such as the International Metastatic RCC Database Consortium (IMDC) risk score, offer only limited insight into the molecular and immunologic complexity of RCC. Emerging molecular biomarkers implicated in resistance mechanisms reflect the underlying heterogeneity of RCC and may inform future therapeutic strategies. Kidney Injury Molecule-1 (KIM-1), a transmembrane protein that is up-regulated in RCC and detectable in circulation, has demonstrated potential as a non-invasive biomarker for diagnosis, prognosis, and treatment monitoring. Liquid-biopsy approaches, including the analysis of circulating tumour DNA (ctDNA), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs), are also gaining traction due to their minimally invasive nature and potential for real-time disease monitoring. This review aims to provide a structured overview of emerging biomarkers in metastatic RCC, critically evaluate their current clinical applicability, and propose a biologically informed framework for their integration into clinical decision-making. In addition, we propose a conceptual IMDC-Plus framework that integrates clinical, biological, and early dynamic markers to improve risk stratification in the era of immunotherapy (IO).

Schlagwörter

Stichwörter der Autor:innen

biomarkerscirculating tumour DNAimmune checkpoint inhibitorsmetastatic renal cell carcinomaprecision oncologypredictive biomarkerstumour microenvironment

Autor:innen und Institutionen

  • Life Sciences Center, Institute of Biosciences, Vilnius University, 01513 Vilnius, Lithuania.
  • Oncology Department, Klaipeda University Hospital, 92288 Klaipeda, Lithuania.
  • Oncology Department, Vilnius University Hospital Santaros Klinikos, 08661 Vilnius, Lithuania.

ORCID-Profile: Edita Baltruskeviciene, Vincas Urbonas

Zitieren

APA

Pikturniene, R., Cesas, A., Jarmalaite, S., Baltruskeviciene, E., & Urbonas, V. (2026). Towards Precision Medicine in Metastatic Renal Cell Carcinoma: The Role of Emerging Biomarkers. Cancers, 18(8), 1228. https://doi.org/10.3390/cancers18081228

Vancouver

Pikturniene R, Cesas A, Jarmalaite S, Baltruskeviciene E, Urbonas V. Towards Precision Medicine in Metastatic Renal Cell Carcinoma: The Role of Emerging Biomarkers. Cancers. 2026;18(8):1228. doi:10.3390/cancers18081228

BibTeX
@article{Pikturniene2026,
  author = {Pikturniene, Rugile and Cesas, Alvydas and Jarmalaite, Sonata and Baltruskeviciene, Edita and Urbonas, Vincas},
  title = {Towards Precision Medicine in Metastatic Renal Cell Carcinoma: The Role of Emerging Biomarkers},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1228},
  doi = {10.3390/cancers18081228}
}
Kostenlos starten →